Transaction DateRecipientSharesTypePriceValue
18th August 2020Edward Raymond Jones4,000Exercise of derivative$3.35$13,400.00
31st July 2020Kathleen P. Bloch10,000Exercise of derivative$5.60$56,000.00
5th May 2020Phillip P. Chan14,100Exercise of derivative$9.39$132,399.00
5th May 2020Vincent Capponi10,123Exercise of derivative$9.26$93,738.98
27th April 2020Vincent Capponi10,000Exercise of derivative$2.88$28,750.00
27th April 2020Vincent Capponi10,000Open or private sale$10.00$100,000.00
12th April 2020Efthymios Deliargyris140,000Grant/award etc.$0.00
10th March 2020Vincent Capponi4,677Exercise of derivative$3.45$16,135.65
10th March 2020Vincent Capponi6,500Exercise of derivative$3.45$22,425.00
10th March 2020Vincent Capponi4,677Open or private sale$6.00$28,062.00
Cytosorbents Corporation
Cytosorbents Corporation logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 3/10.


CytoSorbents Corp. engages in the research and development of blood purification technology. The company was founded by Joseph Rubin on April 25, 2002 and is headquartered in Monmouth Junction, NJ.


Ticker: CTSO
Sector: Healthcare
Industry: Medical Devices
SEC Central Index Key (CIK): 1175151
Employees: 125
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Fundamentals
Cash at Carrying Value: $35 M (0%)
Inventory, Net: $2 M (-6%)
Assets, Current: $42 M (100%)
Property, Plant and Equipment, Net: $2 M (1%)
Other Assets, Noncurrent: $4 M (18%)
Assets: $49 M (79%)
Long-term Debt, Current Maturities: $7 M (0%)
Accounts Payable, Current: $3 M (33%)
Liabilities, Current: $16 M (57%)
Long-term Debt, Excluding Current Maturities: $8 M (0%)
Liabilities: $25 M (4%)
Common Stock, Value, Issued: $37 Th (12%)
Common Stock, Shares, Issued: $37 M (12%)
Retained Earnings (Accumulated Deficit): $195 M (3%)
Accumulated Other Comprehensive Income (Loss), Net of Tax: $530 Th (0%)
Stockholders' Equity (Parent): $24 M (0%)
Liabilities and Equity: $49 M (79%)
Cost of Revenue: $3 M (-42%)
Gross Margin: $7 M (-49%)
Research and Development: $2 M (-44%)
Operating Income/Loss: $3 M (-42%)
Other Income, net: $431 Th (-20%)
Income before taxes: $3 M (-54%)